Pivotal bioVenture Partners Investment Advisor’s Avalyn Pharma AVLN Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio AVLN Stock Details AVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.8M	Buy	+966,792	New	+$27.9M	10.34%	4

Other funds holding AVLN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Andera Partners Paris $206M AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's AVLN Position: Q2 2026 in Review

Pivotal bioVenture Partners Investment Advisor opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 966,792 shares worth $31.8M. The stake represents 10.34% of the portfolio and ranks #4 among its holdings.

38 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

Pivotal bioVenture Partners Investment Advisor held 966,792 shares of Avalyn Pharma worth $31.8M as of Q2 2026.
Avalyn Pharma was a new Pivotal bioVenture Partners Investment Advisor position in Q2 2026.
Avalyn Pharma made up 10.34% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q2 2026, its #4 holding.
38 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2026, filed 13 Aug 2026.